Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment expenses reviewed by the CDMO

The following table provides R&D expenses by program with a reconciliation to net loss for the periods indicated, which are regularly reviewed by the CODM:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
	(in thousands)
Collaboration and other revenue	$	—		$	11,000		$	—		$	11,000
Program expenses:
Mecbotamab vedotin, BA3011 (CAB AXL-ADC)	$	1,315			2,770		$	7,307			11,603
Ozuriftamab vedotin, BA3021 (CAB ROR2-ADC)		824			2,593			4,109			7,157
Evalstotug, BA3071 (CAB CTLA-4)		734			2,095			3,958			7,150
BA3182 (CAB EpCAM x CAB CD3)		2,384			1,352			5,460			3,728
Other CAB Programs		974			2,615			2,773			5,873
Total program expenses		6,231			11,425			23,607			35,511
Personnel and related		2,109			2,970			7,712			9,740
Equity-based compensation		491			1,071			1,833			3,314
Facilities and other		708			929			2,426			2,880
Total research and development expenses		9,539			16,395			35,578			51,445
General and administrative expenses
Personnel and related		1,577			1,951			5,257			5,857
Equity-based compensation		801			1,123			2,481			3,676
Facilities and other		1,872			2,801			6,734			7,721
Total general and administrative expenses		4,250			5,875			14,472			17,254
Interest and other income (loss)		(1,989	)		684			227			2,807
Net loss and comprehensive loss	$	(15,778	)	$	(10,586	)	$	(49,823	)	$	(54,892	)